The state of Arizona has launched a legal battle against cosmetics giant L'Oréal, accusing the company of deliberately concealing evidence that its popular hair relaxer products could lead to cancer in women. This move makes Arizona the inaugural state to directly sue over these alleged risks, joining a growing wave of over 12,000 similar lawsuits filed by individual users and their families across the nation.
Arizona Attorney General Kristin Mayes, a Democrat, initiated the lawsuit late Thursday in state court. The filing contends that L'Oréal violated state consumer protection statutes by actively marketing hair relaxers—products predominantly used by African American women—without adequately warning consumers about the purported connections to ovarian and uterine cancers.
The state is seeking substantial penalties and damages, alongside a court injunction that would compel L'Oréal to cease sales of these products unless clear cancer risk warnings are prominently displayed.
According to Arizona's complaint, L'Oréal and its associated entities, over several decades, "exploited centuries of social pressures and discriminatory beauty standards affecting people of African descent, all while prioritizing profit over consumer safety" in their marketing efforts towards women and children.
This state-level action arrives as L'Oréal faces a massive multidistrict litigation (MDL) proceeding in a Chicago federal court. The MDL, designed to streamline numerous lawsuits from various jurisdictions, currently consolidates more than 12,000 similar claims against the company.
A L'Oréal spokesperson did not provide an immediate comment on the Arizona lawsuit. However, the company has previously asserted that its products undergo stringent safety reviews and has expressed confidence that the claims against them lack legal or scientific merit.
Products like Dark and Lovely and Optimum, marketed to permanently straighten textured hair, are at the heart of these legal challenges.
The surge in lawsuits began following the publication of a 2022 study by the National Institutes of Health. This research indicated that women who frequently used these hair relaxer products were more than twice as likely to develop uterine cancer.
The plaintiffs in these cases are seeking compensation for pain and suffering, as well as economic damages covering medical expenses and product costs. Beyond L'Oréal, other manufacturers, including Revlon, are also named in the lawsuits. Revlon, too, has publicly denied any correlation between its products and cancer risks.
Court records indicate that the multidistrict litigation is progressing, with initial trials potentially commencing as early as next year.
